Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan-Feb;27(1):76-82.
doi: 10.1097/PPO.0000000000000503.

"Triple-Negative Breast Cancer Central Nervous System Metastases From the Laboratory to the Clinic"

Alexandra S Zimmer  1
Affiliations
Review

"Triple-Negative Breast Cancer Central Nervous System Metastases From the Laboratory to the Clinic"

Alexandra S Zimmer. Cancer J. 2021 Jan-Feb.

Abstract

Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancers and has an incidence as high as 50% of brain metastases once patients develop advanced disease. The lack of targeted and effective therapies, characteristic of this subtype of breast cancer, is especially evident once central nervous system (CNS) metastases occur. Compared with other subtypes of breast cancer, TNBC patients have the shorter interval from diagnosis to development of brain metastases and the shorter overall survival once they occur, a median of 4 to 6 months. Preclinical studies of TNBC and CNS microenvironment are actively ongoing, clarifying mechanisms and orienting more effective approaches to therapy. While the first drugs have been specifically approved for use in metastatic TNBC, data on their CNS effect are still awaited.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. Ca-a Cancer Journal for Clinicians 2020;70:7–30. - PubMed
    1. Arvold ND, Oh KS, Niemierko A, et al. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Research and Treatment 2012;136:153–60. - PubMed
    1. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic Behavior of Breast Cancer Subtypes. Journal of Clinical Oncology 2010;28:3271–7. - PubMed
    1. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America 2001;98:10869–74. - PMC - PubMed
    1. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of Distant Recurrence and Clinical Outcomes in Patients With Metastatic Triple-negative Breast Cancer High Incidence of Central Nervous System Metastases. Cancer 2008;113:2638–45. - PMC - PubMed

Publication types